ViTAA Medical’s Aortic Surgery Tool Receives FDA Approval
ViTAA Medical has achieved a significant milestone by getting FDA clearance for its aortic surgery planning tool. This is an important step in the company’s mission to develop a comprehensive platform for aortic care.
The tool, called AiORTA Plan, utilizes artificial intelligence to aid doctors in preparing for complex aortic surgeries. It automatically generates critical preoperative measurements, such as analyzing aneurysms, creating centerlines, and performing volumetric assessments. This cloud-based technology aims to enhance accuracy in surgical procedures and lessen the need for manual planning.
Based in Canada, ViTAA plans to expand its offerings with additional tools: AiORTA Maps and AiORTA Watch, creating a complete AiORTA vascular care platform. AiORTA Maps employs AI with CT scans to give surgeons valuable insights into blood vessel health, including information on thrombus burden, which refers to blood clots inside the blood vessels. It also helps predict potential outcomes.
Once the data collection is finished, the AiORTA Maps tool generates a regional aortic weakness (RAW) Score. This score, developed based on 15 years of research and over 200 tissue samples, helps doctors pinpoint vulnerable areas in the aorta more accurately. ViTAA plans to integrate indications of critical wall weakness into the AiORTA Plan once Maps is commercially available.
Currently, AiORTA Maps is being used in a prospective study to gather imaging and clinical data from patients with aortic aneurysm disease, as noted in clinical study records. Research involving AiORTA Maps is being conducted at 40 sites across the U.S.
The final part of ViTAA’s AiORTA platform is AiORTA Watch, which aims to provide real-time monitoring of aortic health.
Dr. Randy Moore, the Chief Medical Officer at ViTAA, expressed that the FDA clearance supports their vision of blending automation with precision medicine. He emphasized their commitment to developing solutions that help doctors move beyond traditional size guidelines to gain deeper insights into vessel behavior, improving patient care.
Future projections show that the use of AI in healthcare is expected to reach a valuation of $19 billion by 2027. AI technologies are increasingly becoming integral in diagnostic imaging across various healthcare fields. Recently, other companies, like Naitive Technologies and Heartflow, also received FDA clearances for their AI-powered solutions in evaluating bone density and assessing plaque buildup, respectively.
